Clinical OMICs - Issue 8 - (Page 16)

Clinical OMICs NEW PRODUCTS CMV-Monitoring Assay for Organ Transplant Patients The artus® CMV RGQ MDx Kit for human cytomegalovirus (CMV) is a PCR-based assay designed for low- to mid-throughput testing of CMV, which is primarily used as an aid in managing solid organ transplant patients to assess viral load in response to antiviral drug therapy. The assay has a turnaround time of approximately three hours and runs on the Rotor-Gene Q MDx real-time PCR platform. Qiagen www.qiagen.com AMD Genetic Testing Expanded access to Sequenom Laboratories' RetnaGene™ portfolio of laboratory-developed genetic tests is now available in the U.S. The RetnaGene portfolio includes RetnaGene AMD and RetnaGene LR, specialized genetic tests that assess an individual's risk for advanced agerelated macular degeneration (AMD). The RetnaGene tests examine relevant genetic markers to predict advanced AMD risk. Nicox www.nicox.com Hematologic and Solid Cancer Proﬁles Fragile X Carrier and Thyroid Cancer Tests The Xpansion Interpreter® and miRInform® Thyroid tests are now both available in all 50 states. The Xpansion Interpreter is an FMR1 test that determines the total number of CGG repeats and number of AGG interruptions, which can aid in personalizing the risk for at-risk patients of having a child with Fragile X syndrome. The miRInform Thyroid test interrogates 17 different genetic changes including 14 DNA hotspot mutations in BRAF and K-, H-, and N-RAS genes, along with three RNA translocations (RET-PTC1, RET-PTC3, and PAX8/PPARγ). Asuragen www.asuragen.com 16 Clinical OMICs August 13, 2014 Twenty-three NeoTYPE™ Cancer Profiles based on nextgeneration sequencing (NGS) have been launched that allow oncologists and pathologists the ability to tailor cancer testing to individual patient needs. NeoTYPE plasma-based testing using NGS is now available for AML prognostic, CLL prognostic, JMML, lymphoma, MDS/ CMML, MPN, and a 54-gene myeloid disorders profile. The NeoTYPE solid tumor tests, designed to provide coverage of "actionable" molecular abnormalities found specifically in the tested tumor, are available for brain, breast, cervix, colorectal, endometrial, esophageal, gastrointestinal stromal, lung, melanoma, ovarian, soft tissue, thyroid, and other solid tumors. NeoGenomics www.neogenomics.com www.clinicalomics.com http://www.nicox.com http://www.qiagen.com http://www.neogenomics.com http://www.asuragen.com http://www.clinicalomics.com

Table of Contents for the Digital Edition of Clinical OMICs - Issue 8

Contents

Clinical OMICs - Issue 8